Literature DB >> 8375749

Deferoxamine treatment during early pregnancy: absence of teratogenicity in two cases.

E Vaskaridou1, K Konstantopoulos, D Kyriakou, D Loukopoulos.   

Abstract

We report two cases of transfusion-dependent thalassemia treated by deferoxamine during the first trimesters of two successful pregnancies. The absence of any sign(s) of toxicity or teratogenicity is remarkable; despite the data from animal models, it seems that deferoxamine in humans is rather harmless for the fetus at the usually recommended doses.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8375749

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  5 in total

Review 1.  Clinical applications of commonly used contemporary antidotes. A US perspective.

Authors:  C A Bowden; E P Krenzelok
Journal:  Drug Saf       Date:  1997-01       Impact factor: 5.606

2.  A case of severe pyruvate kinase deficiency in a primigravida: successful outcome.

Authors:  Sahar Mohamed; Kenga Sivarajah; Seema Chakravarti
Journal:  Obstet Med       Date:  2013-05-03

3.  Normal pregnancy in a patient with β-thalassaemia major receiving iron chelation therapy with deferasirox (Exjade®).

Authors:  Dimitra Vini; Philippos Servos; Marouso Drosou
Journal:  Eur J Haematol       Date:  2011-01-25       Impact factor: 2.997

4.  The reproduction in women affected by cooley disease.

Authors:  Carlo Pafumi; Vito Leanza; Luana Coco; Stefania Vizzini; Lilliana Ciotta; Alessandra Messina; Gianluca Leanza; Giuseppe Zarbo; Alfio D'Agati; Marco Antonio Palumbo; Alessandra Iemmola; Ferdinando Antonio Gulino; Maria Cristina Teodoro; Matthew Attard; Alina Cristina Plesca; Catarina Soares; Nina Kouloubis; Mayada Chammas
Journal:  Hematol Rep       Date:  2011-03-23

Review 5.  Pregnancy in women with thalassemia: challenges and solutions.

Authors:  George Petrakos; Panagiotis Andriopoulos; Maria Tsironi
Journal:  Int J Womens Health       Date:  2016-09-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.